SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

NCT00440271 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: tipranavir
DRUG: ritonavir
DRUG: Optimized Background Regimen (OBR)

Sponsor

Boehringer Ingelheim